Vestcor Inc Purchases 591 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Vestcor Inc grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 9.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,653 shares of the medical equipment provider’s stock after buying an additional 591 shares during the quarter. Vestcor Inc’s holdings in Lantheus were worth $595,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus during the 4th quarter worth approximately $27,000. UMB Bank n.a. lifted its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares in the last quarter. World Investment Advisors LLC purchased a new stake in shares of Lantheus during the 3rd quarter worth approximately $60,000. Finally, RiverPark Advisors LLC purchased a new stake in shares of Lantheus during the 3rd quarter worth approximately $74,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH opened at $101.10 on Monday. The company has a fifty day moving average price of $92.07 and a 200-day moving average price of $96.68. The firm has a market capitalization of $6.92 billion, a P/E ratio of 16.82 and a beta of 0.38. Lantheus Holdings, Inc. has a one year low of $56.44 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on LNTH shares. JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial lifted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $132.86.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.